Teixobactin Development for Anthrax

Information

  • Research Project
  • 10078521
  • ApplicationId
    10078521
  • Core Project Number
    R44AI152657
  • Full Project Number
    1R44AI152657-01A1
  • Serial Number
    152657
  • FOA Number
    PA-19-272
  • Sub Project Id
  • Project Start Date
    6/15/2020 - 4 years ago
  • Project End Date
    5/31/2023 - a year ago
  • Program Officer Name
    LIU, BAOYING
  • Budget Start Date
    6/15/2020 - 4 years ago
  • Budget End Date
    5/31/2021 - 3 years ago
  • Fiscal Year
    2020
  • Support Year
    01
  • Suffix
    A1
  • Award Notice Date
    6/15/2020 - 4 years ago

Teixobactin Development for Anthrax

ABSTRACT The goal of this project is to continue developing teixobactin (TXB) as an antibiotic to combat weaponized anthrax. This work will be done in parallel to an ongoing preclinical development program, which is advancing TXB for treating infections caused by other serious pathogens such as methicillin resistant Staphylococcus aureus (MRSA). TXB has shown excellent efficacy in several animal models of infection, including a rabbit model of inhalation anthrax recently run at the University of Texas Medical Branch (Galveston, TX). Due to TXB?s unusual mechanism of action ? binding two different bacterial cell wall targets, neither of which is a protein ? TXB represents an example of a compound that is exceptionally free of resistance development and thus is an excellent candidate as a countermeasure for anthrax. The work in this grant will include the following Specific Aims: Aim 1 will provide at least 50 grams of non-cGMP teixobactin to fulfill all studies in the proposal. In addition, at least 200 grams of cGMP material will be produced at a contract manufacturer for planned future studies. Aim 2 will focus on the following studies to further understand TXB?s in vitro properties: (a) MIC testing against a panel of key B. anthracis isolates, including isolates resistant to current anthrax drugs; (b) determine B. anthracis resistance frequency to teixobactin; and (c) protein binding studies using rabbit, nonhuman primate (NHP), and human serum to determine free drug levels. Aim 3 will determine the minimal therapeutic TXB dose in the rabbit anthrax efficacy model, with associated pharmacokinetic (PK) profiling and histopathology. The information in Aim 3, in addition to the toxicology, safety and PK/PD studies being run in parallel with this project, will help inform NHP and human dosing. At the conclusion of this grant, TXB will be prepared to enter a GLP-compliant, NHP inhalation anthrax study and a Phase I clinical study, all in support of FDA approval for treating anthrax under the Animal Rule.

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R44
  • Administering IC
    AI
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    999978
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    855
  • Ed Inst. Type
  • Funding ICs
    NIAID:999978\
  • Funding Mechanism
    SBIR-STTR RPGs
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    NOVOBIOTIC PHARMACEUTICALS, LLC
  • Organization Department
  • Organization DUNS
    140692976
  • Organization City
    CAMBRIDGE
  • Organization State
    MA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    021381068
  • Organization District
    UNITED STATES